Menora Mivtachim Holdings LTD. Has $85.55 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Menora Mivtachim Holdings LTD. reduced its stake in Thermo Fisher Scientific Inc. by 21.6%, holding 171,932 shares valued at $85.55 million after selling 47,379 shares.
• Multiple institutional investors, including Mondrian Investment Partners LTD. and Deutsche Bank AG, have either increased or initiated stakes in Thermo Fisher, highlighting ongoing institutional interest in the company.
• Several analysts have updated their price targets for Thermo Fisher, with a consensus average target of $593.00, reflecting an overall "Moderate Buy" rating from 15 analysts.

Menora Mivtachim Holdings LTD. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 171,932 shares of the medical research company's stock after selling 47,379 shares during the period. Menora Mivtachim Holdings LTD.'s holdings in Thermo Fisher Scientific were worth $85,553,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $30,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter worth about $35,000. Navigoe LLC bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $37,000. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on TMO. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Finally, Barclays raised their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,400 shares of company stock valued at $8,345,792 in the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $10.3950 during mid-day trading on Tuesday, reaching $497.9350. 2,573,648 shares of the company traded hands, compared to its average volume of 3,033,676. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $188.03 billion, a PE ratio of 22.27, a price-to-earnings-growth ratio of 2.60 and a beta of 0.74. The stock has a fifty day simple moving average of $436.43 and a 200-day simple moving average of $458.25.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.